China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Qinhuangdao Zizhu Pharmaceutical, received the Certificate of Suitability to Monograph of European Pharmacopoeia for the raw drug material, Dienogest.
Dienogest helps reduce the occurrence of acne and seborrhea and it is used to treat endometriosis, according to a Shanghai Stock Exchange disclosure on Thursday.
The certificate increased the domestic and foreign customers' recognition of the product, which could have a positive impact on its expansion in the international market, the Chinese pharmaceutical company said in the disclosure.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.